

Company Announcement
ASX: HPC

DATE: 24/5/2024

Further Updates to Change of Board Composition

Hydration solutions company **The Hydration Pharmaceuticals Company Limited (ASX: HPC)** ("**Hydralyte**" or "**the Company**") is pleased to announce that further to the change of Board composition announced on 23 April 2024, and as part of the Company's continuous review of Board skills and composition, Mr Nick Berry will be appointed as a non-executive Director, effective 25 May 2024.

Mr Nick Berry's appointment as non-executive director will be effective following the resignation of Mr George Livery on 25 May 2024.

Nick Berry brings over 19 years of experience in the Australian finance industry, specialising in equity and debt capital markets, mergers and acquisitions and strategic planning. With a proven track record in raising capital and structuring and negotiating complex financial transactions, Nick has demonstrated extensive expertise and leadership in the field. He previously served as an Executive Director at Nomura Australia and is currently a Director of PURE Asset Management Pty Ltd.

Nick holds a Master of Engineering (MEng) from the University of Bath and is a Member of the Australian Institute of Company Directors.

The Company also previously advised that Mr Oliver Baker would be appointed as the Managing Director effective 25 May 2024. Due to a delay in processing Mr Oliver Baker's Director ID application, Mr Baker's appointment as Managing Director will be postponed until such time that the Board confirms receipt of his Director ID. Mr Baker will not receive additional compensation as a result of his appointment as Managing Director.

An Appendix 3X in respect of Mr Berry and Mr Baker will be lodged with ASX following their respective appointments.

ENDS

This announcement was authorised for release by the Board of HydraLyte.

For further information:

Investors/Media

Henry Jordan

Six Degrees Investor Relations

0431 271 538

henry.jordan@sdir.com.au